Clinical review

Treatment of the common cold

Sherif B Mossad, clinical associate. 

Department of Infectious Diseases, Cleveland Clinic Foundation, Cleveland, Ohio, USA

The common cold is the most frequent illness managed in general practice. Despite a long search for a cure only potential treatments for the symptoms have been established. Colds afflict most adults two to four times a year and children four to eight times a year, and the resulting hours of absenteeism from work or school have enormous economic bearings. Several viruses can cause the common cold, but rhinoviruses are by far the most common. Studies evaluating various treatments for the common cold are divided into experimentally induced and naturally occurring colds. Treatments studied included symptomatic measures, pharmacological blockers, and specific antiviral agents, as well as drugs with yet unestablished mechanism of action. A systematic, evidence based assessment of this literature is imperative for rational selection of treatmentif anyfor patients with a common cold.

	Methods

I reviewed articles cited in Medline between 1966 and 1997 using the keywords common cold, treatment, therapy, and drug treatment. I selected well designed randomised, double blind, placebo controlled trials and authoritative review articles on specific topics in treatment of the common cold. Articles published within the past five years were selected rather than earlier articles when appropriate. Out of 334 articles retrieved, 49 articles were selected for this review.

	Antihistamines

Top Methods Discussion References

First generation antihistamines have achieved the most favourable results in both naturally occurring and experimentally induced common colds. Oral doxylamine succinate,¹ clemastine fumarate,² and chlorpheniramine maleate³ significantly reduced rhinorrhoea, sneezing, and weight of nasal secretions but had minimal effects on other cold symptoms. The effective dose varied depending on the compound studied. Drowsinessa common side effectcan actually help patients whose colds disturb their sleep if the drug is taken at bed time. Long acting antihistamines such as terfenadine that are used for allergic rhinitis are not as effective, probably because of their lack of anticholinergic activity.⁴

	Anticholinergics

Top Methods Discussion References

Intranasal ipratropium bromide spray significantly reduced nasal drainage and sneezing in studies of naturally occurring colds.^5-7 The optimum dose used in these studies was 84 µg (two sprays of a 0.06% solution in buffered saline solution) in each nostril three to four times daily. The main side effects included nasal dryness, occasional epistaxis, and headache. The duration of relief of rhinorrhoea was not well defined but thought to be over three hours. These data suggest that inhaled anticholinergics could be useful for the average cold.

	Adrenergic agonists

Top Methods Discussion References

These substances are potent decongestants and have been long used for treating the common cold. Both oral and nasal forms proved effective in natural and experimental cold models. ^{8 9} These drugs are not without hazards, however, and prolonged use can lead to a rebound effect (rhinitis medicamentosa). Care needs to be taken in patients with hypertension because of the sympathomimetic effect of these drugs.

	Steam inhalation

Top Methods Discussion References

Breathing in steam from a bowl or jug is widely believed to ease the soreness and discomfort of a cold. Nasal hyperthermia (42⁰-44⁰C) administered for natural or experimental common colds resulted in subjective improvement of symptoms and objective increased nasal patency in two studies from Israel and the United Kingdom. ^{10 11} Attempts to reproduce these findings in the United States were unsuccessful. ^{12 13} Possible explanations given for this discrepancy included variations in the technique of administering steam and different strains of viruses involved. It is a cheap and safe treatment for patients who find it helpful.

	Mast cell stabilisers

Top Methods Discussion References

Nedocromil and sodium cromoglycate administered intranasally or by inhalation have been shown to reduce the severity of naturally and experimentally induced rhinovirus upper respiratory tract infections.^14-15 These drugs prevent the release of chemical mediators in response to infection and down regulate the intracellular adhesion molecule type 1 (the receptor for rhinovirus) in the inflamed airway epithelium. However, they have no effect on the frequency of viral shedding or the serological response to infection. Even though the safety profile of these drugs is excellent, they have not yet been evaluated in large epidemiological studies.

	Non-steroidal anti-inflammatory drugs

Top Methods Discussion References

Aspirin as well as other non-steroidal anti-inflammatory drugs has been suggested to increase nasal symptoms and virus shedding and decrease serum neutralising antibody response in volunteers infected with rhinovirus. ^{16 17} More recently, the cyclo-oxygenase inhibitor naproxen was found to reduce headache, malaise, and cough without altering virus shedding or antibody responses in experimentally induced rhinovirus colds.¹⁸

	Vitamin C

Top Methods Discussion References

During the past three decades numerous studies have assessed the potential role of vitamin C in the treatment or prevention of common cold. In 1975 Chalmers reviewed the available literature and published a meta-analysis concluding that "the minor benefits of questionable validity are not worth the potential risk, no matter how small that might be." ¹⁹ A more recent analysis of the same review by Hemila pointed out several errors and suggested that vitamin C significantly decreases the duration of episodes and the severity of symptoms of the common cold by an average of 23%.²⁰ The best dose of vitamin C for the treatment of the common cold was not determined, but the maximal benefit was not thought to be obtained with 1 g/day of the vitamin.²¹

	Glucocorticoids

Top Methods Discussion References

Farr et al found that intranasal and systemic glucocorticoids were ineffective in preventing experimental rhinovirus infection, although nasal inflammation was transiently suppressed initially.²² Another study found no therapeutic value for oral prednisone in experimental rhinovirus infections. Although it reduced kinin concentrations in nasal washes, mean viral titres were higher in the steroid group.²³

	Antibiotics

Top Methods Discussion References

In a recent American survey 21% of all antibiotic prescriptions for adults by ambulatory care doctors were for upper respiratory tract infections.²⁴ Another survey found that 60% of patients seen in primary care for the common cold received a prescription for an anti- biotic.²⁵ A conservative estimate of the annual cost of antibiotic prescribing for the common cold in the United States in 1994 was $37.5 million. Overuse of antibiotics was widespread across states and medical specialties. This is obviously an important factor in the increase of drug resistant bacteria.

A well designed study from Switzerland found co-amoxiclav was beneficial in only the 20% of patients with common cold whose nasopharyngeal secretions contained Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae.²⁶ Nevertheless, attempting to apply these findings might increase the overuse of antibiotics. A reasonable alternative strategy would be to ask patients to return in a few days if their illness does not improve with treatment of the symptoms.

	Zinc

Top Methods Discussion References

Eight controlled trials on the use of zinc to treat the common cold have been published. Four of these showed a beneficial effect and four did not. ^{27 28} There are several plausible explanations for this discrepancy, including differences in the efficacy of the formulation or dose used and different viruses involved. Some formulations, such as zinc citrate, might render zinc ions inactive. Doses well above the minimal daily requirements are needed to attain a therapeutic benefit. Concerns were also raised regarding the adequacy of the placebo used in some of these studies.²⁹

The exact mechanism through which zinc affects the common cold remains to be determined. One hypothesis is that zinc prevents rhinovirus from binding to the respiratory intracellular adhesion molecule type 1 on the epithelium, thus blocking viral entry into the cells.³⁰ Other hypotheses include inhibition of viral capsid protein synthesis, a membrane stabilising effect, inhibiting prostaglandin metabolites, and increasing production of interferon.

	Interferon

Top Methods Discussion References

Numerous studies have been conducted to evaluate the effect of intranasal interferon alfa on both natural and experimental colds. Results varied depending on the form of administration of interferon (spray v drops), dose given, frequency of administration, type of virus causing the illness, and whether interferon was given for prophylaxis or treatment. Interferon alfa-2b had some prophylactic efficacy in naturally occurring³¹ and experimentally induced³² rhinovirus colds when given before symptoms developed. The main side effect was local nasal irritation, dryness, and bleeding, which may be confused with nasal symptoms due to rhinovirus infection itself. Therefore, even though interferon is a powerful antiviral drug, it is not useful for treating colds.

View larger version (171K): [in this window] [in a new window]   A rhinovirus particle

	Specific antiviral drugs

Top Methods Discussion References

Influenza virus infections have been successfully treated with drugs such as amantadine, rimantadine, and zanamivir.³³ On the other hand, several studies using antiviral drugs against rhinovirus colds showed no appreciable clinical benefit,^34-35 even though in vitro studies gave promising results.³⁶ These drugs share a common mechanism of action, binding to specific hydrophobic pockets in the virion capsid and inhibiting virion attachment or uncoating.³⁷ The main obstacles for the development of effective antiviral drugs for the common cold include the wide variety of causative agents, mutant strains, and development of resistance. As with interferon, capsid binding drugs have no effect when given after symptoms have developed, and the local adverse effects of intranasal formulations may mask some of their beneficial effects.

	Combination of agents

Top Methods Discussion References

Numerous combinations of agents used for symptomatic or specific treatment of the common cold have been assessed and several other combinations remain to be evaluated. Combinations of  agonists with antihistamine and anticholinergics were not effective in relieving symptoms of the common cold in adults⁹ or children,³⁸ while an  agonist combined with a non-steroidal anti-inflammatory drug resulted in a significant reduction in rhinorrhoea.³⁹ A critical review of clinical trials between 1950 and 1991 evaluating over-the-counter cold remedies demonstrated lack of effectiveness in preschool children, although adolescents and adults clearly benefited from certain combinations.⁴⁰ Patients should pay attention to the active ingredients of these combinationsfor instance, most include a cough suppressive, which is probably not needed early on in the course of a cold.

	Other agents

Top Methods Discussion References

Aqueous iodine (2%) was successfully used to interrupt transmission of rhinovirus infection when applied to susceptible volunteers' fingers.⁴¹ Although 2% aqueous iodine is cosmetically impractical, similar compounds with less staining properties might be appropriate, particularly in preventing transmission between family members. The expectorant guaifenesin had a marginal antitussive effect compared with placebo in young adults with natural colds but decreased sputum thickness and quantity.⁴²

	Discussion

Top Methods Discussion References

Many of the studies reviewed here were conducted at the Common Cold Unit at Harvard Hospital in Salisbury and the Department of Internal Medicine at the University of Virginia Health Sciences Center in Charlottesville, Virginia, United States. Other excellent reviews on the subject have been published in the past 10 years. ^{43 44} In presenting these data, I decided not to perform a formal meta-analysis because the number of well designed published studies was very large, study designs were variable, and analysis of outcome was inconsistent. Many studies relied on subjective reporting of symptoms, making interpretation of the results difficult. The virus challenge model and the natural cold model both have their advantages and disadvantages.⁴⁵ Almost all experimentally induced studies used rhinovirus, which is epidemiologically sound but obviously provides an incomplete answer.

Methods of treating the common cold can be grouped into three categories: symptomatic measures such as anticholinergics; pharmacological blockers such as non-steroidal anti-inflammatory drugs; and antivirals such as interferon alfa-2b. An important obstacle to developing an effective treatment for the common cold is that viral replication in the upper respiratory tract peaks on the day symptoms start. Therefore, the key element in many of these studies was to start treatment within 24 hours of the onset of symptoms.

Much of the overuse of cold remedies can be ascribed to doctors' behaviour. A recent study in a family practice teaching clinic estimated that 26% of patients seen for upper respiratory tract infections were given unnecessary drugs.⁴⁶ Doctors may mistakenly believe that patient satisfaction depends on receiving medicines, whereas taking time to educate patients about medicines and about when it is necessary to see a doctor would be more appropriate.⁴⁷ Two thirds of families possess several over-the-counter cold medications,⁴⁸ so the potential for toxicity, particularly in children, is considerable; in the United States 6.2% of all poisonings in children in 1996 were with cough and cold preparations.⁴⁹

Several limitations to this review should be recognised. Firstly, any database search may miss certain articles because of different key words or changing headings. Secondly, some manufacturers may use unpublished data from company trials to support the use of their products. Thirdly, studies of naturally occurring common cold in different parts of the world may be evaluating different viruses, and studies of experimentally induced cold can assess only certain types of the many possible viral culprits.

In summary, treatment of symptoms remains the best available option for the common cold. Other promising agents include mast cell stabilisers, interferon alfa-2b, and zinc lozenges. Some combination of drugs might be the most logical answer, but cost and compliance remain significant practical problems.. Meanwhile, our responsibility is to avoid unnecessary and potentially harmful medications and to educate our patients when to seek medical advice and about the effectiveness, or lack of effectiveness, of the available treatments.

	References

Top Methods Discussion References

1. Eccles R, Van Cauwenberge P, Tetzloff W, Borum P. A clinical study to evaluate the efficacy of the antihistamine doxylamine succinate in the relief of runny nose and sneezing associated with upper respiratory tract infection. J Pharm Pharmacol 1995; 47: 990-993[Medline].
2. Gwaltney Jr JM, Park J, Paul RA, Edelman DA, O'Connor RR, Turner RB. Randomized controlled trial of clemastine fumarate for treatment of experimental rhinovirus colds. Clin Infect Dis 1996; 22: 656-662[Medline].
3. Howard Jr JC, Kantner TR, Lilienfield LS, Princiotto JV, Krum RE, Crutcher JE, et al. Effectiveness of antihistamines in the symptomatic management of the common cold. JAMA 1979; 242: 2414-2417[Abstract].
4. Gaffey MJ, Kaiser DL, Hayden FG. Ineffectiveness of oral terfenadine in natural colds: evidence against histamine as a mediator of common cold symptoms. Pediatr Infect Dis J 1988; 7: 223-228[Medline].
5. Borum P, Olsen L, Winther B, Mygind N. Ipratropium nasal spray: a new treatment for rhinorrhea in the common cold. Am Rev Respir Dis 1981; 123: 418-420[Medline].
6. Diamond L, Dockhorn RJ, Grossman J, Kisicki JC, Posner M, Zinny MA, et al. A dose-response study of the efficacy and safety of ipratropium bromide nasal spray in the treatment of the common cold. J Allergy Clin Immunol 1995; 95: 1139-1146[Medline].
7. Hayden FG, Diamond L, Wood PB, Korts DC, Wecker MT. Effectiveness and safety of intranasal ipratropium bromide in common colds: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996; 125: 89-97[Abstract/Free Full Text].
8. Akerlund A, Klint T, Olen L, Rundcrantz H. Nasal decongestant effect of oxymetazoline in the common cold: an objective dose-response study in 106 patients. J Laryngol Otol 1989; 103: 743-746[Medline].
9. Sperber SJ, Sorrentino JV, Riker DK, Hayden FG. Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bull NY Acad Med 1989; 65: 145-160[Medline].
10. Ophir D, Elad Y. Effects of steam inhalation on nasal patency and nasal symptoms in patients with the common cold. Am J Otolaryngol 1987; 3: 149-153.
11. Tyrrell D, Barrow I, Arthur J. Local hyperthermia benefits natural and experimental common colds. BMJ 1989; 289: 1280-1283.
12. Forstall GJ, Macknin ML, Yen-Lieberman B, Medendorp SV. Effect of inhaling heated vapor on symptoms of the common cold. JAMA 1994; 271: 1109-1111[Abstract].
13. Hendley JO, Abott RD, Beasley PP, Gwaltney Jr JM. Effect of inhalation of hot humidified air on experimental rhinovirus infection. JAMA 1994; 271: 1112-1113[Abstract].
14. Barrow GI, Higgins PG, Al-Nakib W, Smith AP, Wenham PBM, Tyrrell AJ. The effect of intranasal nedocromil sodium on viral upper respiratory tract infections in human volunteers. Clin Exp Allergy 1990; 20: 45-51[Medline].
15. Aberg N, Aberg B, Alestig K. The effect of inhaled and intranasal sodium cromoglycate on symptoms of upper respiratory tract infections. Clin Exp Allergy 1996; 26: 1045-1050[Medline].
16. Stanley ED, Jackson GG, Panusarn C, Rubenis M, Dirda V. Increased virus shedding with aspirin treatment of rhinovirus infection. JAMA 1975; 231: 1248-1251[Abstract].
17. Graham NMH, Burrell CJ, Douglas RM, Debelle P, Davies L. Adverse effects of aspirin, acetaminophen and ibuprofen on immune function, viral shedding and clinical status in rhinovirus-infected volunteers. J Infect Dis 1990; 162: 1277-1282[Medline].
18. Sperber SJ, Hendley O, Hayden FG, Riker DK, Sorrentino JV, Gwaltney Jr JM. Effects of naproxen on experimental rhinovirus colds: a randomized, double-blind, controlled trial. Ann Intern Med 1992; 117: 37-41.
19. Chalmers TC. Effects of ascorbic acid on the common cold: an evaluation of the evidence. Am J Med 1975; 58: 532-536[Medline].
20. Hemila H, Herman ZS. Vitamin C and the common cold: a retrospective analysis of Chalmers' review. J Am Coll Nutr 1995; 14: 116-123[Abstract].
21. Hemila H. Does vitamin C alleviate the symptoms of the common cold? A review of current evidence. Scand J Infect Dis 1994; 26: 1-6[Medline].
22. Farr BM, Gwaltney Jr JM, Hendley JO, Hayden FG, Naclerio RM, McBride T, et al. A randomized controlled trial of glucocorticoid prophylaxis against experimental rhinovirus infection. J Infect Dis 1990; 162: 1173-1177[Medline].
23. Gustafson LM, Proud D, Hendley JO, Hayden FG, Gwaltney Jr JM. Oral prednisone therapy in experimental rhinovirus infections. J Allergy Clin Immunol 1996; 97: 1009-1014[Medline].
24. Gonzales R, Steiner JF, Sande MA. Antibiotic prescribing for adults with colds, upper respiratory tract infections and bronchitis by ambulatory care physicians. JAMA 1997; 278: 901-904[Abstract].
25. Mainous III AG, Hueston WJ, Clark JR. Antibiotics and upper respiratory infection: do some folks think there is a cure for the common cold ? J Fam Pract 1996; 42: 357-361[Medline].
26. Kaiser L, Lew D, Hirschel B, Auckenthaler R, Morabia A, Heald A, et al. Effects of antibiotic treatment in the subset of common cold patients who have bacteria in nasopharyngeal secretions. Lancet 1996; 347: 1507-1510[Medline].
27. Potter YJ, Hart LL. Zinc lozenges for treatment of common colds. Ann Pharmacother 1993; 27: 589-592[Medline].
28. Mossad SB, Macknin ML, Medendorp SV, Mason P. Zinc gluconate lozenges for treating the common cold: a randomized, double-blind, placebo-controlled study. Ann Intern Med 1996; 125: 81-88[Abstract/Free Full Text].
29. Farr BM, Gwaltney Jr. JM. The problems of taste in placebo matching: an evaluation of zinc gluconate for the common cold. J Chron Dis 1987; 40: 875-879[Medline].
30. Novick SG, Godfrey JC, Godfrey NJ, Wlder HR. How does zinc modify the common cold? Clinical observation and implications regarding mechanism of action. Med Hypotheses 1996; 46: 295-302[Medline].
31. Farr BM, Gwaltney Jr JM, Adams KF, Hayden FG. Intranasal interferon-2 for prevention of natural rhinovirus colds. Antimicrob Agents Chemother 1984; 26: 31-34[Abstract/Free Full Text].
32. Samo TC, Greenberg SB, Couch RB, Quarles J, Johnson PE, Hook S, et al. Efficacy and tolerance of intranasally applied recombinant leukocyte A interferon in normal volunteers. J Infect Dis 1983; 148: 535-542[Medline].
33. Hayden FG, Osterhaus ADME, Treanor JJ, Fleming DM, Aoki FY, Nicholson KG, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. N Engl J Med 1997; 337: 874-880[Abstract/Free Full Text].
34. Al-Nakib W, Higgins PG, Barrow GI, Tyrrell DAJ, Andries K, Vanden Bussche G, et al. Suppression of colds in human volunteers challenged with rhinovirus by a new synthetic drug (R61837). Antimicrob Agents Chemother 1989; 33: 522-525[Abstract/Free Full Text].
35. Hayden FG, Hipskind GJ, Woerner DH, Eisen GF, Janssens M, Janssen PAJ, et al. Intranasal Pirodavir (R77,975) treatment of rhinovirus colds. Antimicrob Agents Chemother 1995; 39: 290-294[Abstract/Free Full Text].
36. Dolovich MB, Mahony JB, Chambers C, Newhouse MT, Chernesky MA. Ciliary function, cell viability and in vitro effect of ribavirin on nasal epithelial cells in acute rhinorrhea. Chest 1992; 102: 284-287[Abstract/Free Full Text].
37. McKinlay MA, Pevear DC, Rossmann MG. Treatment of the picornavirus common colds by inhibitors of viral uncoating and attachment. Annu Rev Microbiol 1992; 46: 635-654[Medline].
38. Doyle WJ, Riker DK, McBride TP, Hayden FG, Hendley JO, Swarts JD, et al. Therapeutic effects of an anticholinergic-sympathomimetic combination in induced rhinovirus colds. Ann Otol Rhinol Laryngol 1993; 102: 521-527[Medline].
39. Clemens CJ, Taylor JA, Almquist JR, Quinn HC, Mehta A, Naylor GS. Is an antihistamine-decongestant combination effective in temporarily relieving symptoms of the common cold in preshcool children? J Pediatr 1997; 130: 463-466[Medline].
40. Smith MB, Feldman W. Over-the-counter cold medications: a critical review of clinical trials between 1950 and 1991. JAMA 1993; 269: 2258-2263[Abstract].
41. Gwaltney Jr JM, Moskalski PB, Hendley JO. Interruption of experimental rhinovirus transmission. J Infect Dis 1980; 142: 811-815[Medline].
42. Kuhn JJ, Hendley JO, Adams KF, Clark JW, Gwaltney Jr JM. Antitussive effect of guaifenesin in young adults with natural colds: objective and subjective assessment. Chest 1982; 82: 713-718[Abstract/Free Full Text].
43. Kirkpatrick GL. The common cold. Primary Care 1996; 23: 657-675[Medline].
44. Lowenstein SR, Parrino TA. Management of the common cold. Adv Intern Med 1987; 32: 207-234[Medline].
45. Gwaltney JM, Buier RM, Rogers JL. The influence of signal variation, bias, noise and effect size on statistical significance in treatment studies of the common cold. Antiviral Research 1996; 29: 287-295[Medline].
46. English JA, Mauman KA. Evidence-based management of upper respiratory infection in a family practice teaching clinic. Fam Med 1997; 29: 38-41[Medline].
47. Roberts CR, Imrey PB, Turner JD, Hosokawa MC, Alster JM. Reducing physician visits for colds through consumer education. JAMA 1983; 250: 1986-1989[Abstract].
48. Maiman LA, Becker MH, Cummings KM, Drachman RH, O'Connor PA. Effects of sociodemographic and attitudinal factors on mother-initiated medication behavior for children. Public Health Reports 1982; 97: 140-149[Medline].
49. Litovitz TL, Smilkstein M, Felberg L, Klein-Schwartz W, Berlin R, Morgan JL. 1996 Annual report of poison control centers toxic exposure surveillance system. Am J Emerg Med 1997; 15: 447-500[Medline].